Nezih Karaca and Nebahat Demet Akpolat
Objective: Androgenetic Alopecia (AGA) is one of the three most common forms of noncicatricial alopecia characterized by hair loss in both men and women. It occurs in 50% of men above in their sixth decade. Currently, two effective treatments for AGA are used in men: topical minoxidil and oral finasteride. However, although clinical studies have shown that minoxidil and finasteride have positive therapeutic outcomes, their use can have certain side-effects. In this study, we aimed to compare the safety and effectiveness of an alternative treatment, Redensyl, Capixyl, and Procapil (RCP), and 5% minoxidil solution in adult male patients suffering from AGA.
Methods: This randomized controlled study was conducted on patients who used either RCP or 5% minoxidil for 24 weeks. The patients applied 1 mL of each solution to their head skin twice each day, in the morning and evening.
Results: The comparison between RCP and minoxidil groups revealed that patients treated with RCP had a significantly higher researcher score (minoxidil group 25.5% vs. RCP group 64.7%), higher global photographic evaluation score (minoxidil: 60% vs. RCP: 88.9%), and higher self-evaluation score.
Conclusion: The RCP group showed a significantly better clinical recovery in terms of hair growth.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 